COMPANY

Reunion Neuroscience

Keywords: psychiatry generalized anxiety disorder adjustment disorder major depressive disorder Postpartum Depression Lactation RE104

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series A · amount not disclosed · announced Sep 16, 2025 Company release ↗
Source quote
- Sep 16, 2025 · Company release ↗
  “16 Sep Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD) — Upsized Series A Financing Brings Total Amount Raised to $133 Million — — GAD Affects 3.1% of U.S.”
Raise Series A · $103M · announced May 2, 2024 Company release ↗
Source quote
- May 2, 2024 · Company release ↗
  “Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with underserved”

Raises announced in these releases: $103M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Apr 20, 2026 Trial start Phase 2: RE104 Safety and Efficacy Study in Generalized Anxiety Disorder source ↗
Sep 16, 2025 Raise Private equity round — Series A: $133M (total, as published), announced Sep 16, 2025. Source: company's own press page. source ↗
Sep 16, 2025 Raise Series A · amount not disclosed source ↗
Aug 19, 2025 Trial start Phase 1: RE104 Radiolabeled Mass Balance (hAME) Study source ↗
Jul 30, 2025 Trial start Phase 2: RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses source ↗
Nov 13, 2024 Trial start Phase 1: RE104 Clinical Lactation Study source ↗
Jun 14, 2024 Trial start Phase 2: RE104 Safety and Efficacy Study in Postpartum Depression source ↗
May 2, 2024 Raise Series A · $103M source ↗

2026-11 (ESTIMATED) · Phase 2 · RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses · NCT07002034
2027-07 (ESTIMATED) · Phase 2 · RE104 Safety and Efficacy Study in Generalized Anxiety Disorder · NCT07489651

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $133.0M. Last 2 years.

Sep 16, 2025 Private equity round — Series A: $133M (total, as published), announced Sep 16, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07489651	RE104 Safety and Efficacy Study in Generalized Anxiety Disorder	Phase 2	Recruiting	Apr 20, 2026	2027-07 (estimated)
NCT07002034	RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Recruiting	Jul 30, 2025	2026-11 (estimated)
NCT06342310	RE104 Safety and Efficacy Study in Postpartum Depression	Phase 2	Completed	Jun 14, 2024	May 22, 2025 (actual)
NCT07146191	RE104 Radiolabeled Mass Balance (hAME) Study	Phase 1	Completed	Aug 19, 2025	Oct 2, 2025 (actual)
NCT06659263	RE104 Clinical Lactation Study	Phase 1	Completed	Nov 13, 2024	May 28, 2025 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of MPM BioImpact (captured Oct 12, 2026). portfolio page ↗